Terms: = Uterine cancer AND uPA AND Prognosis
14 results:
1. Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma.
Hwang JR; Cho YJ; Ryu JY; Choi JY; Choi JJ; Sa JK; Kim HS; Lee JW
Biomed Pharmacother; 2023 Dec; 168():115792. PubMed ID: 37924789
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathological features and immunophenotype of Silva pattern system in endocervical adenocarcinoma.
Zeng C; Wu JK; Lu X
Int J Exp Pathol; 2023 Jun; 104(3):140-150. PubMed ID: 36928883
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Abbink K; Zusterzeel PLM; Geurts-Moespot A; van der Steen R; Span PN; Sweep FCGJ
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1725-1735. PubMed ID: 32394054
[TBL] [Abstract] [Full Text] [Related]
4. Siegesbeckia orientalis Extract Inhibits TGFβ1-Induced Migration and Invasion of Endometrial cancer Cells.
Chang CC; Ling XH; Hsu HF; Wu JM; Wang CP; Yang JF; Fang LW; Houng JY
Molecules; 2016 Aug; 21(8):. PubMed ID: 27527140
[TBL] [Abstract] [Full Text] [Related]
5. A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
Dariusz S; Agnieszka M; Elzbieta R; Danuta ON; Maciej Z; Piotr D; Nowicki M
Eur J Obstet Gynecol Reprod Biol; 2012 Aug; 163(2):193-9. PubMed ID: 22525297
[TBL] [Abstract] [Full Text] [Related]
6. Role of urokinase-type plasminogen activator (upa) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
[TBL] [Abstract] [Full Text] [Related]
8. [Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia].
Gerstein ES; Gritsaenko EV; Shcherbakov ME; Shcherbakov AM; Ognerudov NA; Kushlinskiĭ NE
Vopr Onkol; 2003; 49(6):725-9. PubMed ID: 14976916
[TBL] [Abstract] [Full Text] [Related]
9. High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer.
Borgfeldt C; Bendahl PO; Gustavsson B; Långström E; Fernö M; Willén R; Grenman S; Casslén B
Int J Cancer; 2003 Nov; 107(4):658-65. PubMed ID: 14520707
[TBL] [Abstract] [Full Text] [Related]
10. Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance.
Roggel F; Hocke S; Lindemann K; Sinz S; Welk A; Bosl M; Pabst M; Nusser N; Braun S; Schmitt M; Harbeck N
Recent Results Cancer Res; 2003; 162():89-100. PubMed ID: 12790324
[TBL] [Abstract] [Full Text] [Related]
11. High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer.
Nordengren J; Fredstorp Lidebring M; Bendahl PO; Brünner N; Fernö M; Högberg T; Stephens RW; Willén R; Casslén B
Int J Cancer; 2002 Jan; 97(3):379-85. PubMed ID: 11774293
[TBL] [Abstract] [Full Text] [Related]
12. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract] [Full Text] [Related]
13. Tumor-associated proteolytic factors upa and PAI-1 in endometrial carcinoma.
Köhler U; Hiller K; Martin R; Langanke D; Naumann G; Bilek K; Jänicke F; Schmitt M
Gynecol Oncol; 1997 Aug; 66(2):268-74. PubMed ID: 9264575
[TBL] [Abstract] [Full Text] [Related]
14. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Kobayashi H; Fujishiro S; Terao T
Cancer Res; 1994 Dec; 54(24):6539-48. PubMed ID: 7987854
[TBL] [Abstract] [Full Text] [Related]
